Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure

PHASE1UnknownINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

October 31, 2008

Study Completion Date

September 30, 2010

Conditions
Carcinoma, Transitional CellBladder Neoplasms
Interventions
BIOLOGICAL

Oncolytic adenovirus (serotype 5) - CG0070

Intravesical administration of CG0070 (in suspension) directly into the bladder

Trial Locations (10)

10032

Columbia University, New York

12208

New York Oncology Hematology, Albany

29605

Cancer Centers of the Carolinas, Greenville

59107

Billings Clinic, Billings

75246

Mary Crowley Medical Research Center, Dallas

77030

Baylor College of Medicine, Houston

85032

BCG Oncology, Phoenix

94143

UCSF Comprehensive Cancer Center, San Francisco

L4M 7G1

Male/Female Health and Research Centre, Barrie

L6H 3P1

The Fe/Male Health Centre, Oakville

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cell Genesys

INDUSTRY

NCT00109655 - Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure | Biotech Hunter | Biotech Hunter